{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:37:47Z","timestamp":1792046267604,"version":"4.4.0"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"\n Importance<\/jats:title>\n Methylphenidate is the leading pharmacological treatment for attention-deficit\/hyperactivity disorder (ADHD) in childhood and adolescence. Individuals with ADHD have a higher risk of psychosis, but the long-term relationship between methylphenidate and risk of developing psychotic disorders is unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To estimate the relationship between methylphenidate treatment and the risk of nonaffective psychosis in children and adolescents diagnosed with ADHD.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study included instrumental variable analysis of data linkage from multiple national Finnish registries for all individuals born from 1987 to 1997 (n\u2009=\u2009697\u202f289). These registries were used to identify childhood and adolescent ADHD diagnoses (age &amp;lt;18 years) from 2003 onwards. Data were analyzed from June 2023 to December 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Cumulative amount of treatment with methylphenidate used in 4 intervention windows: within 1, 2, 3, and 4 years after ADHD diagnosis. Hospital district prescribing propensities (average prescribing within each hospital district, within each intervention window) were used as instruments.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n \n Diagnosis of nonaffective psychotic disorder (by code from\n International Statistical Classification of Diseases and Related Health Problems, Tenth Revision<\/jats:italic>\n ) by the end of follow-up (December 31, 2016). Instrumental variable analyses were conducted using 2-stage least squares modeling and the Anderson-Rubin test. Risk differences (RDs) were estimated for each intervention window.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 3956 individuals diagnosed with ADHD (3181 male [80.4%], 775 female [19.6%]; median [IQR] age, 14.16 [11.78-15.93] years), 2728 (69.0%) received methylphenidate at least once. A total of 222 individuals (5.7%) were diagnosed with nonaffective psychosis by mean (SD) age 22.16 (2.39) years (range, 19.00-29.81 years). There was substantial variation in hospital district prescribing propensity (for example, first-year range, 0.07 to 0.30). Instrumental variable analysis indicated that sustained treatment with methylphenidate (30 mg\/d) was not associated with the risk of nonaffective psychosis in the overall ADHD sample (1-year RD, \u22120.14; 95% CI, \u22120.85 to 0.42; and 4-year RD, \u22120.15; 95% CI, \u22120.49 to 0.11). Secondary analyses indicated a reduced risk of nonaffective psychosis among individuals diagnosed in childhood (age &amp;lt;13 years: 3-year RD, \u20130.24; 95% CI, \u20130.45 to \u20130.03;\n P<\/jats:italic>\n \u2009=\u2009.03; 4-year RD, \u20130.21; 95% CI, \u20130.48 to \u20130.07;\n P<\/jats:italic>\n \u2009=\u2009.02). An insufficiently strong instrument precluded the same secondary analyses in those diagnosed in adolescence.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion and Relevance<\/jats:title>\n This study of national Finnish registry data for individuals with ADHD found no overall relationship between sustained treatment with methylphenidate risk of nonaffective psychosis; in secondary analyses, a potentially protective effect of methylphenidate treatment against later psychosis in children diagnosed with ADHD was found. Further research is needed to evaluate potential effects of treatment in individuals diagnosed in adolescence and adulthood.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2026.0152","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:30:36Z","timestamp":1774452636000},"page":"611","source":"Crossref","is-referenced-by-count":3,"title":["Methylphenidate Treatment and Risk of Psychotic Disorder"],"prefix":"10.1001","volume":"83","author":[{"given":"Colm","family":"Healy","sequence":"first","affiliation":[{"name":"Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh, United Kingdom"},{"name":"School of Medicine, University College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirstie","family":"O\u2019Hare","sequence":"additional","affiliation":[{"name":"Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"L\u00e5ng","sequence":"additional","affiliation":[{"name":"Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh, United Kingdom"},{"name":"Faculty of Medicine, University of Oulu, Oulu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Mets\u00e4l\u00e4","sequence":"additional","affiliation":[{"name":"Clinical Medicine Research Unit, University of Oulu and Oulu University Hospital, Oulu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pulakka","sequence":"additional","affiliation":[{"name":"Research Unit of Population Health, University of Oulu, Oulu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"McGrath","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Migone","sequence":"additional","affiliation":[{"name":"St John of God Community Services CAMHS, Rathgar, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Keating","sequence":"additional","affiliation":[{"name":"St John of God Hospitaller Services Group, Stillorgan, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Romaniuk","sequence":"additional","affiliation":[{"name":"Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gyllenberg","sequence":"additional","affiliation":[{"name":"Department of Adolescent Psychiatry, Helsinki University Hospital, Helsinki, Finland"},{"name":"Research Centre for Child Psychiatry and INVEST-flagship, University of Turku, Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eero","family":"Kajantie","sequence":"additional","affiliation":[{"name":"Clinical Medicine Research Unit, University of Oulu and Oulu University Hospital, Oulu, Finland"},{"name":"Population Health Knowledge Base Team, Finnish Institute for Health and Welfare, Helsinki, Finland"},{"name":"Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Perrett","sequence":"additional","affiliation":[{"name":"Department of Applied Statistics, Social Science, and the Humanities, New York University, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Applied Statistics, Social Science, and the Humanities, New York University, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Elwert","sequence":"additional","affiliation":[{"name":"Department of Sociology, University of Wisconsin\u2013Madison, Madison"},{"name":"Department of Biostatistics and Medical Informatics, University of Wisconsin\u2013Madison, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Kelleher","sequence":"additional","affiliation":[{"name":"Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh, United Kingdom"},{"name":"School of Medicine, University College Dublin, Dublin, Ireland"},{"name":"Faculty of Medicine, University of Oulu, Oulu, Finland"},{"name":"St John of God Hospitaller Services Group, Stillorgan, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"yoi260008r1","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/ije\/dyt261","article-title":"ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis.","volume":"43","author":"Polanczyk","year":"2014","journal-title":"Int J Epidemiol"},{"issue":"3","key":"yoi260008r3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009885.pub3","article-title":"Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).","volume":"3","author":"Storeb\u00f8","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"yoi260008r4","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-2528","article-title":"Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents.","volume":"144","author":"Wolraich","year":"2019","journal-title":"Pediatrics"},{"issue":"6","key":"yoi260008r5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1177\/1087054715605915","article-title":"Recent trends in stimulant usage.","volume":"20","author":"Safer","year":"2016","journal-title":"J Atten Disord"},{"issue":"15","key":"yoi260008r6","first-page":"1515","article-title":"Aktiivisuuden ja tarkkaavuuden h\u00e4iri\u00f6n (ADHD) l\u00e4\u00e4kkeiden k\u00e4ytt\u00f6 on yleistynyt.","volume":"134","author":"Vuori","year":"2018","journal-title":"Duodecim"},{"issue":"1","key":"yoi260008r7","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.70253","article-title":"Increase in occurrence of attention deficit hyperactivity disorder differs by age group and gender: Finnish Nationwide Register Study.","volume":"15","author":"Westman","year":"2025","journal-title":"Brain Behav"},{"issue":"12","key":"yoi260008r8","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/NEJMoa1813751","article-title":"Psychosis with methylphenidate or amphetamine in patients with ADHD.","volume":"380","author":"Moran","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"yoi260008r9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1001\/jamapsychiatry.2020.4799","article-title":"Association of attention-deficit\/hyperactivity disorder in childhood and adolescence with the risk of subsequent psychotic disorder: a systematic review and meta-analysis.","volume":"78","author":"Nourredine","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"yoi260008r10","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1001\/jamapsychiatry.2025.2311","article-title":"Occurrence of psychosis and bipolar disorder in individuals with attention-deficit\/hyperactivity disorder treated with stimulants: a systematic review and meta-analysis.","volume":"82","author":"Salazar de Pablo","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"yoi260008r11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.21307\/sjcapp-2018-003","article-title":"Hallucinations and other psychotic symptoms in response to methylphenidate in children and adolescents with attention-deficit\/hyperactivity disorder: a Cochrane systematic review with meta-analysis and trial sequential analysis.","volume":"6","author":"Ramstad","year":"2018","journal-title":"Scand J Child Adolesc Psychiatr Psychol"},{"issue":"5","key":"yoi260008r12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012069.pub2","article-title":"Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents: assessment of adverse events in non-randomised studies.","volume":"5","author":"Storeb\u00f8","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"yoi260008r13","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S2215-0366(19)30189-0","article-title":"Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study.","volume":"6","author":"Hollis","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"yoi260008r14","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1542\/peds.2008-0185","article-title":"Hallucinations and other psychotic symptoms associated with the use of attention-deficit\/hyperactivity disorder drugs in children.","volume":"123","author":"Mosholder","year":"2009","journal-title":"Pediatrics"},{"issue":"11","key":"yoi260008r15","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.216","article-title":"Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system.","volume":"6","author":"Man","year":"2016","journal-title":"Transl Psychiatry"},{"issue":"1","key":"yoi260008r16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41380-021-01161-7","article-title":"Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies.","volume":"27","author":"Solmi","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"1-2","key":"yoi260008r17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.schres.2015.08.033","article-title":"Attention-deficit\/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population-based study in Taiwan.","volume":"168","author":"Shyu","year":"2015","journal-title":"Schizophr Res"},{"issue":"6","key":"yoi260008r18","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2024-069142","article-title":"Stimulant medication use and risk of psychotic experiences.","volume":"155","author":"O\u2019Hare","year":"2025","journal-title":"Pediatrics"},{"issue":"13","key":"yoi260008r19","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/sim.6128","article-title":"Instrumental variable methods for causal inference.","volume":"33","author":"Baiocchi","year":"2014","journal-title":"Stat Med"},{"issue":"1","key":"yoi260008r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.leaqua.2022.101673","article-title":"Instrumental variables estimation: assumptions, pitfalls, and guidelines.","volume":"34","author":"Bastardoz","year":"2023","journal-title":"Leadersh Q"},{"issue":"8","key":"yoi260008r21","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1017\/S0033291724000321","article-title":"Mendelian randomization: causal inference leveraging genetic data.","volume":"54","author":"Chen","year":"2024","journal-title":"Psychol Med"},{"issue":"8","key":"yoi260008r22","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1001\/jamapsychiatry.2017.1378","article-title":"Association of electroconvulsive therapy with psychiatric readmissions in US hospitals.","volume":"74","author":"Slade","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"yoi260008r23","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/hec.4227","article-title":"Instrumental variable-based assessment of the effect of psychotherapy on suicide attempts, health, and economic outcomes in schizophrenia.","volume":"30","author":"Blaehr","year":"2021","journal-title":"Health Econ"},{"issue":"22","key":"yoi260008r24","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa052827","article-title":"Risk of death in elderly users of conventional vs. atypical antipsychotic medications.","volume":"353","author":"Wang","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"yoi260008r25","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.jclinepi.2010.09.006","article-title":"Use of instrumental variable in prescription drug research with observational data: a systematic review.","volume":"64","author":"Chen","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"yoi260008r26","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s11096-016-0299-0","article-title":"Methods to control for unmeasured confounding in pharmacoepidemiology: an overview.","volume":"38","author":"Uddin","year":"2016","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"yoi260008r27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jaac.2023.05.025","article-title":"Effect of pharmacological treatment of attention-deficit\/hyperactivity disorder on criminality.","volume":"63","author":"Widding-Havneraas","year":"2024","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"yoi260008r28","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/aje\/kwr448","article-title":"Comparison of instrumental variable analysis using a new instrument with risk adjustment methods to reduce confounding by indication.","volume":"175","author":"Fang","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"3","key":"yoi260008r29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1080\/08039480801983596","article-title":"The validity of schizophrenia diagnosis in the Finnish Hospital Discharge Register: findings from a 10-year birth cohort sample.","volume":"62","author":"Pihlajamaa","year":"2008","journal-title":"Nord J Psychiatry"},{"issue":"6","key":"yoi260008r30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/1403494812456637","article-title":"Quality of the Finnish Hospital Discharge Register: a systematic review.","volume":"40","author":"Sund","year":"2012","journal-title":"Scand J Public Health"},{"issue":"4","key":"yoi260008r31","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1007\/s10578-015-0591-6","article-title":"Demographic characteristics and psychiatric comorbidity of children and adolescents diagnosed with ADHD in specialized healthcare.","volume":"47","author":"Joelsson","year":"2016","journal-title":"Child Psychiatry Hum Dev"},{"issue":"10","key":"yoi260008r33","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1007\/s00787-025-02735-4","article-title":"Duration of ADHD medication treatment among Finnish children and adolescents: a nationwide register study.","volume":"34","author":"Kolari","year":"2025","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"6","key":"yoi260008r35","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s00787-023-02294-6","article-title":"Effect of ADHD medication on risk of injuries: a preference-based instrumental variable analysis.","volume":"33","author":"Widding-Havneraas","year":"2024","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"yoi260008r37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-economics-092123-111021","article-title":"A practical guide to weak instruments.","volume":"16","author":"Keane","year":"2024","journal-title":"Annu Rev Econ"},{"key":"yoi260008r39","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1214\/aoms\/1177730090","article-title":"Estimation of the parameters of a single equation in a complete system of stochastic equations.","volume":"20","author":"Anderson","year":"1949","journal-title":"Ann Math Stat"},{"issue":"3","key":"yoi260008r41","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s40471-018-0152-1","article-title":"Understanding the assumptions underlying instrumental variable analyses: a brief review of falsification strategies and related tools.","volume":"5","author":"Labrecque","year":"2018","journal-title":"Curr Epidemiol Rep"},{"issue":"10","key":"yoi260008r42","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1257\/aer.20211063","article-title":"Valid t-ratio inference for IV.","volume":"112","author":"Lee","year":"2022","journal-title":"Am Econ Rev"},{"issue":"10","key":"yoi260008r43","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1176\/appi.ajp.2015.14101266","article-title":"Is adult ADHD a childhood-onset neurodevelopmental disorder? evidence from a four-decade longitudinal cohort study.","volume":"172","author":"Moffitt","year":"2015","journal-title":"Am J Psychiatry"},{"issue":"3","key":"yoi260008r44","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1192\/bjp.2018.97","article-title":"Young adult mental health and functional outcomes among individuals with remitted, persistent and late-onset ADHD.","volume":"213","author":"Agnew-Blais","year":"2018","journal-title":"Br J Psychiatry"},{"issue":"1","key":"yoi260008r45","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2024-301521","article-title":"Risk of hospitalisation for first-onset psychosis or mania within a year of ADHD medication initiation in adults with ADHD.","volume":"28","author":"Gudbrandsdottir","year":"2025","journal-title":"BMJ Ment Health"},{"issue":"5","key":"yoi260008r46","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/mp.2017.170","article-title":"Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group.","volume":"23","author":"Kelly","year":"2018","journal-title":"Mol Psychiatry"},{"issue":"1","key":"yoi260008r47","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1148\/radiol.2019182528","article-title":"White matter by diffusion MRI following methylphenidate treatment: a randomized control trial in males with attention-deficit\/hyperactivity disorder.","volume":"293","author":"Bouziane","year":"2019","journal-title":"Radiology"},{"issue":"11","key":"yoi260008r48","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1111\/j.1460-9568.2008.06254.x","article-title":"Juvenile methylphenidate modulates reward-related behaviors and cerebral blood flow by decreasing cortical D3 receptors.","volume":"27","author":"Andersen","year":"2008","journal-title":"Eur J Neurosci"},{"issue":"1","key":"yoi260008r49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/104454601750143366","article-title":"Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters.","volume":"11","author":"Moll","year":"2001","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"yoi260008r50","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/s41380-021-01391-9","article-title":"The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit\/hyperactivity disorder in children and adolescents: a meta-analysis.","volume":"27","author":"Farhat","year":"2022","journal-title":"Mol Psychiatry"},{"key":"yoi260008r2","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"},{"key":"yoi260008r38","year":"2023"},{"key":"yoi260008r32","unstructured":"Kruuti? J; Social Insurance Institution of Finland, Finnish Medicines Agency. Finnish statistics on medicines 2020: Medicine reimbursement system and approval of medicine prices. 2021. Accessed February 19, 2026. https:\/\/www.julkari.fi\/bitstream\/handle\/10024\/143552\/Finnish_statistics_on_medicines_2020.pdf?sequence=1andisAllowed=y"},{"key":"yoi260008r34","unstructured":"Working group appointed by Finnish Medical Society Duodecim, Finnish Society for Child and Adolescent Psychiatry, and Finnish Society for Adolescent Psychiatry. ADHD (attention-deficit hyperactivity disorder): current care guidelines; April 4, 2019. Accessed February 19, 2026. http:\/\/www.kaypahoito.fi"},{"key":"yoi260008r36","unstructured":"World Health Organization. Anatomical Therapeutic Chemical (ATC) classification. Accessed August 19, 2025. https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/atc-classification"},{"key":"yoi260008r40","unstructured":"Finlay? K, Magnusson? L, Schaffer? ME; Boston College Department of Economics. WEAKIV: Stata module to perform weak-instrument-robust tests and confidence intervals for instrumental-variable (IV) estimation [Statistical Software Components S457684]; 2013. Accessed February 19, 2026. https:\/\/ideas.repec.org\/c\/boc\/bocode\/s457910.html"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2846833\/jamapsychiatry_healy_2026_oi_260008_1779900171.06463.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:00:34Z","timestamp":1780498834000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2846833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.0152","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}